Fiona Lindo
Urogynecology and Reconstructive Pelvic Surgery · Houston, TXNPI 1962653279
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (50.7%), education and consulting fees — rather than concentrated in one kind of arrangement. 32 manufacturers reported payments, led by Applied Medical Resources Corporation at 56.9% of the total. Among urogynecology and reconstructive pelvic surgery clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 189 payments — averaging $350.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Applied Medical Resources Corporation$38K
- Boston Scientific$12K
- Intuitive Surgical$12K
- Renovia Inc$722
- Caldera Medical, Inc$559
- Astellas Pharma US Inc$441
- plus $2K from 26 others
What the payments were for
- Consulting fees$8,01012%
- Speaking & faculty fees$33,54551%
- Travel & lodging$5,8739%
- Food & beverage$6,72410%
- Education$12,02218%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Applied Medical Resources Corporation | 42 | $37,626 |
| Boston Scientific | 38 | $12,488 |
| Intuitive Surgical | 7 | $12,196 |
| Renovia Inc | 9 | $722 |
| Caldera Medical, Inc | 7 | $559 |
| Astellas Pharma US Inc | 23 | $441 |
| Johnson & Johnson | 9 | $383 |
| Medtronic | 2 | $314 |
| Coloplast | 2 | $204 |
| Axonics, Inc. | 4 | $177 |
| AbbVie(2 entities) | 8 | $170 |
| Pfizer | 11 | $161 |
| Coopersurgical, Inc. | 4 | $144 |
| Allotrope Medical, Inc | 1 | $96 |
| Sumitomo Pharma America, Inc. | 2 | $70 |
| Bluewind Medical | 2 | $41 |
| Baxter Healthcare | 1 | $41 |
| Octapharma USA, Inc. | 1 | $40 |
| Pacira Pharmaceuticals Incorporated | 1 | $35 |
| Therapeuticsmd, Inc. | 2 | $29 |
| Ambu Inc. | 2 | $26 |
| Femselect Inc. | 1 | $25 |
| Medical Device Business Services, Inc. | 1 | $24 |
| Avion Pharmaceuticals | 1 | $23 |
| AMAG Pharmaceuticals, Inc. | 1 | $22 |
| Duchesnay USA Incorporated | 1 | $21 |
| Dilon Technologies, Inc. | 1 | $20 |
| Lupin Inc. | 1 | $18 |
| Teleflex LLC | 1 | $16 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Antares Pharma, Inc. | 1 | $14 |
| Cumberland Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- GelPOINT V-Path$33,213
- Da Vinci Surgical System$12,158
- GENERAL - THERAPIES$8,570
- Advantage System$1,545
- Solyx SIS System$551
- Leva Pelvic Floor Trainer$550
- Desara$351
- GENERAL FEMALE SUI$345
- EVARREST$250
- LigaSure$247
- ADVANTAGE$240
- Vertessa$199
- ALTIS$180
- Axonics$131
- Axonics r-SNM System$128
- UPSYLON$125
- STRATAFIX$120
- Uterine Manipulators & Injectors$112
- SOLYX$110
- GENERAL PELVIC ORGAN PROLAPSE$100
How this compares
$66,174 in reported general payments places this provider in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
See all urogynecology and reconstructive pelvic surgery providers in Texas →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 51 | $37,277 |
| MyrbetriqMirabegron | 35 | $26,117 |
| Estradiol | 214 | $12,656 |
| Solifenacin Succinate | 18 | $581 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $431 |
| Gabapentin | 51 | $211 |
| Ibuprofen | 46 | $142 |
| Ciprofloxacin Hcl | 42 | $102 |
| Triamcinolone Acetonide | 14 | $57 |
| Tramadol Hcl | 51 | $50 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $70 | $37,27751 claims |
| Astellas Pharma US IncMyrbetriq | $441 | $26,11735 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 urogynecology and reconstructive pelvic surgery providers in Texas.
Other urogynecology and reconstructive pelvic surgery in Houston
- Gazala SiddiquiHouston$81K
- Peter LotzeHouston$48K
- Oluwarotimi NetteyHouston$19K
- Linh DoHouston$11K
- Christine PanHouston$11K
- Apurva PancholyHouston$10K
- Danielle AntoshHouston$8K
- Khadijah EidHouston$8K
- Emily RutledgeHouston$5K
- Sarah RozyckiHouston$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.